TGF-β1 antisense therapy modulates expression of matrix metalloproteinases in keloid-derived fibroblasts

Sadick,H.; Herberger,A.; Riedel,K.; Bran,G.; Goessler,U.; Hoermann,K.; Riedel,F.

doi:10.3892/ijmm.22.1.55

TGF-β1 antisense therapy modulates expression of matrix metalloproteinases in keloid-derived fibroblasts

Authors:
- H. Sadick
- A. Herberger
- K. Riedel
- G. Bran
- U. Goessler
- K. Hoermann
- F. Riedel
View Affiliations

Affiliations: Department of Otolaryngology, Head and Neck Surgery, University Hospital of Mannheim, Theodor-Kutzer-Ufer, D-68135 Mannheim, Germany. haneen.sadick@hno.ma.uni-heidelberg.de
Published online on: July 1, 2008 https://doi.org/10.3892/ijmm.22.1.55
Pages: 55-60

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Transforming growth factor-β1 (TGF-β1) has been identified as an important regulator of wound healing. Recent developments in molecular therapy offer exciting prospects for the modulation of wound healing, specifically those targeting TGF-β1. The purpose of this study was to analyze the effect of TGF-β1 targeting on the expression of matrix metalloproteinases (MMPs) in fibroblasts cultured from earlobe keloids. The expression of MMP-2 and -9 in tissue samples from keloids was investigated by immunohistochemistry. The effect of TGF-β1 targeting using antisense oligonucleotides on the expression of MMPs in keloid-derived fibroblasts was analysed by ELISA and multiplex RT-PCR. Immunohistochemical studies demonstrated an increased expression of MMP protein in tissue samples from keloids compared to normal human skin. Antisense TGF-β1 oligonucleotide treatment significantly downregulated MMP-9 secretion in vitro. In conclusion, TGF-β1 antisense oligonucleotide technology may be a potential therapeutic option for the inhibition of proteolytic tissue destruction in keloids.